ZFIN ID: ZDB-FISH-150901-26522
Fish name: vu12Tg
Genotype: vu12Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by vu12Tg
No data available
GENE EXPRESSION
Gene expression in vu12Tg
RNA expression
Expressed Gene Structure Conditions Figures
alcama standard conditions Fig. 2 from Chung et al., 2013
cdkn1bb standard conditions Fig. 4 from Kim et al., 2012
cdkn1ca standard conditions Fig. 4 from Kim et al., 2012
disc1 standard conditions Fig. 4 with imageFig. 6 with image from Boyd et al., 2015
chemical treatment: Cyclopamine Fig. 6 with image from Boyd et al., 2015
fabp7a standard conditions Fig. 2 from Kim et al., 2008
fzd8a standard conditions Fig. 1 with image from Kim et al., 2008
gad1b standard conditions Fig. 5 with image from Bae et al., 2009
gad2 standard conditions Fig. 5 with image from Bae et al., 2009
gfap standard conditions Fig. 2 with image from Park et al., 2007
id2b standard conditions Fig. 4 from Kim et al., 2012
id4 standard conditions Fig. 4 from Kim et al., 2012
irx3a standard conditions Fig. 2 with image from Kim et al., 2008
isl2a standard conditions Fig. 3 with image from Kim et al., 2008
Fig. 4 with image from Shin et al., 2007
chemical treatment: DAPT Fig. 4 with image from Shin et al., 2007
kif11 standard conditions Fig. 10 with image from Johnson et al., 2014
mbpa standard conditions Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Bae et al., 2009
Fig. 2 with image from Park et al., 2007
chemical treatment: pharmaceutical Fig. 1 with image from Takada et al., 2010
neurog1 standard conditions Fig. 3 with image from Borodovsky et al., 2009
nkx2.2a standard conditions Fig. 2 with image from Kim et al., 2008
nkx6.1 standard conditions Fig. 8 from Zannino et al., 2009
pcna standard conditions Fig. 3 with image from Park et al., 2007
pkd2l1 standard conditions Fig. 8 from Djenoune et al., 2014
prdm12b standard conditions Fig. 1 with image from Zannino et al., 2014
prkci standard conditions Fig. 4 with image from Park et al., 2007
pvalb7 standard conditions Fig. 5 with image from Bae et al., 2009
qki2 standard conditions Fig. 4 from Kim et al., 2012
sim1a standard conditions Fig. 3 with image from Borodovsky et al., 2009
slc17a6b standard conditions Fig. 5 with image from Bae et al., 2009
sox2 standard conditions Fig. 4 with image from Snyder et al., 2012
sox5 standard conditions Fig. 4 from Kim et al., 2012
sox6 standard conditions Fig. 4 from Kim et al., 2012
sox10 standard conditions 19 figures with image from 12 publications
chemical treatment: drug Fig. 5 with image from Kim et al., 2008
tcf4 standard conditions Fig. 4 from Kim et al., 2012
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-aldoc standard conditions Fig. 2 with image from McFarland et al., 2008
Ab1-mnx1 standard conditions Fig. 5 with image from Almeida et al., 2016
Ab18-h3 standard conditions Fig. 5 with image from Almeida et al., 2016
Ab1-rps6 standard conditions Fig. 1 from Mathews et al., 2016
Fig. 4 from Kearns et al., 2015
Ab4-sox10 control Fig. 5 from Kim et al., 2015
zn-8 standard conditions Fig. 3Fig. 6 from Zannino et al., 2009
Fig. 3 with image from Kim et al., 2008
Ab1-tuba standard conditions Fig. 3 with image from Yang et al., 2015
Ab1-calb2 standard conditions Fig. 2 with image from McFarland et al., 2008
Ab4-sox10 chemical treatment: metronidazole, chemical treatment: sulfasalazine Fig. 5 from Kim et al., 2015
Ab2-isl standard conditions Fig. 4 with image from Snyder et al., 2012
Fig. 3Fig. 6 from Zannino et al., 2009
Ab1-prkcz control Fig. 7 with image from Takada et al., 2011
Ab1-fabp7 standard conditions Fig. 2Fig. 3 from Kim et al., 2008
Ab1-pax2 standard conditions Fig. 8 from Zannino et al., 2009
Ab-G3G4 chemical treatment: 5-bromo-2'-deoxyuridine Fig. 4 with image from Kim et al., 2008
Ab-3A10 standard conditions Fig. 5 with image from Almeida et al., 2016
Fig. 1 from Mathews et al., 2014
Ab20-mapk standard conditions Fig. 1 from Mathews et al., 2016
ab1-lhx3/4 standard conditions Fig. 2 with image from Seredick et al., 2014
Ab1-elavl chemical treatment: drug Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Kim et al., 2008
zrf-1 standard conditions Fig. 3 with image from Hudish et al., 2013
Fig. 7 with image from Takada et al., 2011
Fig. 1 with image from Takada et al., 2010
Fig. 8 from Zannino et al., 2009
Fig. 6 with image from Kim et al., 2008
Fig. 4 with imageFig. S1 with image from Kim et al., 2008
Ab1-pvalb standard conditions Fig. 2 with image from McFarland et al., 2008
Ab20-mapk chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
Ab1-rps6 chemical treatment: sirolimus Fig. 1 from Mathews et al., 2016
Fig. 4 from Kearns et al., 2015
Ab1-elavl standard conditions Fig. 2 with image from Shin et al., 2012
Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Bae et al., 2009
Fig. 8 from Zannino et al., 2009
Fig. 5 with image from Kim et al., 2008
Fig. 2 with image from McFarland et al., 2008
zrf-1 chemical treatment: DAPT Fig. 1 with image from Takada et al., 2010
Fig. 6 with image from Kim et al., 2008
Ab1-fabp7a fabp7a standard conditions Fig. 2 from Kim et al., 2008
Ab3-sox2 sox2 standard conditions Fig. 4 with image from Snyder et al., 2012
Ab1-sox10 sox10 standard conditions 16 figures with image from 10 publications
Ab1-sox10 chemical treatment: drug Fig. 1 with image from Takada et al., 2010
Fig. 5 with image from Kim et al., 2008
PHENOTYPE
Phenotype in vu12Tg
Phenotype Conditions Figures
cholesterol biosynthetic process process quality, abnormal chemical treatment: Ro 48-8071 Fig. 7 from Mathews et al., 2014
glioblast (sensu Vertebrata) cell migration in hindbrain decreased occurrence, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) disc1 expression decreased amount, abnormal chemical treatment: Cyclopamine Fig. 6 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) EGFP expression decreased amount, abnormal chemical treatment: Cyclopamine Fig. 6 with imageFig. 7 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) disc1 expression decreased distribution, abnormal chemical treatment: Cyclopamine Fig. 6 with image from Boyd et al., 2015
hindbrain glioblast (sensu Vertebrata) EGFP expression decreased distribution, abnormal chemical treatment: Cyclopamine Fig. 6 with imageFig. 7 with image from Boyd et al., 2015
oligodendrocyte mislocalised dorsally, abnormal chemical treatment: atorvastatin Fig. 4 from Mathews et al., 2014
oligodendrocyte MAPK cascade decreased occurrence, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
oligodendrocyte TOR signaling decreased occurrence, abnormal chemical treatment: sirolimus Fig. 4 from Kearns et al., 2015
oligodendrocyte TOR signaling decreased occurrence, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
oligodendrocyte development process quality, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
oligodendrocyte development process quality, abnormal chemical treatment: atorvastatin Fig. 4 from Mathews et al., 2014
oligodendrocyte development process quality, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
oligodendrocyte differentiation disrupted, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Boyd et al., 2015
oligodendrocyte progenitor proliferation disrupted, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Boyd et al., 2015
protein farnesylation process quality, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
protein geranylgeranylation process quality, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
retina neuroblast (sensu Vertebrata) proliferative, abnormal chemical treatment: pharmaceutical Fig. 8 from Kassen et al., 2009
smoothened signaling pathway involved in ventral spinal cord patterning decreased process quality, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Al Oustah et al., 2014
spinal cord has fewer parts of type oligodendrocyte, abnormal chemical treatment: Cyclopamine Fig. 7 with image from Al Oustah et al., 2014
spinal cord central nervous system myelination process quality, normal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte adjacent to dorsal longitudinal fasciculus, normal chemical treatment: Ro 48-8071 Fig. 7 from Mathews et al., 2014
spinal cord oligodendrocyte ab1-rps6 labeling decreased amount, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
spinal cord oligodendrocyte ab1-rps6 labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 4 from Kearns et al., 2015
spinal cord oligodendrocyte ab20-mapk labeling decreased amount, abnormal chemical treatment by environment: Ro 48-8071 Fig. 1 from Mathews et al., 2016
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte far from dorsal longitudinal fasciculus, abnormal chemical treatment: atorvastatin Fig. 4 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte position, normal chemical treatment: Ro 48-8071 Fig. 7 from Mathews et al., 2014

CITATIONS  (70)